Please ensure Javascript is enabled for purposes of website accessibility

Why Nektar Therapeutics Stock Gained 29% in January

By Demitri Kalogeropoulos – Updated Apr 19, 2019 at 10:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company clawed back some of 2018's losses in the first month of the new year.

What happened

Nektar Therapeutics (NKTR -1.59%) shareholders trounced the market last month as their stock gained 29% compared to an 8% spike in the S&P 500, according to data provided by S&P Global Market Intelligence.

The rally did little to reverse the broader drop in the cancer-treatment specialist's shares, which are down 37% in the past year compared to a 3% uptick in the broader market.

Two scientists studying a microscope.

Image source: Getty Images.

So what

The stage was set for January's rally in part by a difficult 2018 that saw Nektar shares fall by 45%. The company booked just $46 million of revenue over the first three quarters of the year to offset just a small portion of its research and development spending. Promising tumor-attacking treatments haven't paid off as well as investors hoped they would.

Against that backdrop, shares spiked in early January after management's pipeline update showed several of its drug treatments, including NKTR-214, advancing through late-stage clinical trials.

Check out the latest Nektar earnings call transcript.

Now what

Nektar has two notable treatment studies launching in the first few months of 2019. And thanks to its partnership with drug giant Bristol-Myers Squibb, the company has plenty of cash on hand to see it through these clinical tests and many more to come. However, investors appear to be waiting for concrete evidence of commercialization success, which makes sense given that shares are still expensive -- valued at almost seven times the $1.2 billion in revenue that Nektar is expected to book for 2018.

Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.09 (-1.59%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.